Fighting Amyotrophic Lateral Sclerosis by Protecting the Liver? A Prospective Cohort Study

Background Previous studies have observed liver abnormalities in amyotrophic lateral sclerosis (ALS) patients. This study aimed to investigate whether early signs of liver disease, measured by magnetic resonance imaging‐derived iron‐corrected T1‐mapping (cT1), are risk factors for developing ALS. Methods cT1 and proton density fat fraction were measured and automatically analyzed using LiverMultiScan® software. The Fibrosis‐4 index was calculated using an established formula based on age and blood markers. Cox proportional hazard models were used to examine the relationship between liver disease, liver biomarkers, and incident ALS. Results In a cohort of 533,707 individuals from UK Biobank, 24 ALS cases were identified among 28,328 participants with liver disease during the follow‐up period. Among a total of 33,959 individuals with complete liver imaging data, 15 incident ALS cases were observed during a median follow‐up period of 5.6 years. Individuals with liver disease had a higher risk of developing ALS, with an adjusted hazard ratio of 7.35 (95% CI 4.47–12.09; p < 0.001). An increase in cT1 was also associated with a higher risk of ALS. After adjusting for age, sex, Townsend deprivation index, smoking status, alcohol intake frequency, body mass index, proton density fat fraction, Fibrosis‐4, and metabolic syndrome, an increase in cT1 remained significantly associated with a higher risk of ALS, with an adjusted hazard ratio of 3.15 (95% CI 1.79–5.55) per 1‐SD increase. Sensitivity analyses confirmed these robust results. Interpretation Liver disease activity, indicated by cT1, increases the risk of developing ALS, independent of metabolic syndrome, liver fat, or fibrosis. ANN NEUROL 2024